|
Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda |
Speakers' Bureau - Celgene |
|
|
Honoraria - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen-Cilag; Novartis |
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi; Takeda (Inst) |
Speakers' Bureau - Art tempi; Bristol-Myers Squibb; Celgene; Chugai Pharma Europe; Janssen; Novartis |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Novartis; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genesis Pharmaceuticals; Janssen-Cilag; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda |
Research Funding - Amgen (Inst); Janssen-Cilag (Inst) |
Travel, Accommodations, Expenses - Amgen; Genesis Pharmaceuticals; Janssen-Ortho |